NBE Therapeutics
About NBE Therapeutics
NBE Therapeutics was founded in 2012 by Dr. Ulf Grawunder, a seasoned biotech entrepreneur and former CEO/CSO of 4-Antibody, Switzerland, that was recently sold to U.S.-based Agenus (AGEN). Ulf Grawunder, CEO of NBE-Therapeutics, is an expert in the field of fully human therapeutic antibody discovery and engineering and has developed two novel patent-pending technologies for the discovery of fully human antibodies and the generation of next-generation antibody drug conjugates (ADCs).YEAR FOUNDED:
2012
LEADERSHIP:
Founder and CEO: Ulf Grawunder
CSO: Roger R. Beerli
13 articles about NBE Therapeutics
-
Pharma giant Boehringer Ingelheim strengthened its immuno-oncology portfolio this week by inking an acquisition deal with NBE Therapeutics for a tidy $1.4 billion US.
-
Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer
9/8/2020
- Companies will partner to develop novel antibody-drug conjugates using NBE’s unique ADC platform - - Agreement encompasses an exclusive option on multiple targets over a two-year term, with potential to extend time and scope of the collaboration - - Deal is the fourth biologics-focused agreement for Exelixis since 2018 -
-
BioSpace Global Roundup, Jan. 16
1/16/2020
Companies from across the globe provide updates to their business and pipeline. -
NBE-Therapeutics Closes USD 22M Series C Financing Round
1/10/2020
NBE-Therapeutics AG announces the closing of a USD 22M Series C financing round, led by its existing shareholders Boehringer Ingelheim Venture Fund and the PPF Group and with participation from all private shareholders.
-
SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates
11/7/2019
NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate under their existing license and collaboration agreement.
-
BioSpace Movers & Shakers, Oct. 11
10/11/2019
Companies strengthen their leadership teams and boards of directors with these appointments. -
NBE-Therapeutics Appoints Dr. Steffen Heeger as Chief Medical Officer for Leading The Clinical Development of NBE’s iADC Programs
10/8/2019
NBE-Therapeutics AG, a biopharmaceutical company developing best-in-class, immune-stimulatory antibody drug conjugates (iADCs™), announces the appointment of Dr. Steffen Heeger as Chief Medical Officer (CMO).
-
WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership
4/10/2019
NBE-Therapeutics develops next-generation iADC products with the aim to improve the outcome for cancer patients, as it continues to develop iADCs based on its proprietary technology platforms.
-
NBE Therapeutics Closes a CHF 20 Million Financing by Novo Holdings A/S
6/28/2018
NBE Therapeutics AG, today announces a CHF 20 million extension of the Series B round.
-
NBE-Therapeutics Appoints Dr. Nicole Onetto to Its Board of Directors
11/28/2017
Nicole is a medical doctor with over 20 years of industry experience in clinical development of targeted cancer therapies.
-
NBE Therapeutics Expands Board Of Directors By The Appointment Of Hans-Peter Gerber
4/4/2017
-
NBE Therapeutics Raises CHF 20 Million In Series B Funding
11/3/2016
-
SOTIO And NBE Therapeutics Sign Collaboration And License Agreement For Next-Generation Antibody-Drug Conjugates
10/20/2016